Equity Profile
Pre-Earnings Brief
Indivior Pharmaceuticals, Inc. is a healthcare company focused on developing innovative treatments for addiction and mental health disorders....
Earnings Per Share (EPS)
EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
While specific revenue estimates are not available, growth in revenue is critical for assessing the company's market performance and demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
EPS Beat Streak
4Q
EPS Beat Rate
100%
Avg EPS Surprise
+68.40%
Avg Stock Reaction
+9.86%
In Q1-2026, Indivior reported an EPS of $0.96, surpassing expectations by over 50%. The stock reacted positively, increasing by 7.70% the following day.
Management Promises & Guidance
Analysts have high expectations for Indivior, especially given its consistent track record of beating EPS estimates. Investors are keen to see if this trend continues in the upcoming report.
Bull Case
If Indivior can maintain or exceed its previous EPS growth, it could signal robust demand for its products and further stock appreciation.
Bear Case
Conversely, any signs of slowing growth or failure to meet EPS expectations could lead to a significant decline in stock price.
Earnings Per Share (EPS)
$0.96EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.
Revenue Growth
N/AWhile specific revenue estimates are not available, growth in revenue is critical for assessing the company's market performance and demand for its products.
Expectations
The print will turn on these two things.
Q1
Will Indivior's EPS exceed $0.96, maintaining its streak of positive surprises?
Given the company's history of beating EPS estimates, this will be a critical indicator of ongoing financial health.
Q2
What are the growth prospects for their addiction treatment products?
Understanding the demand for their products will help gauge future revenue growth and market position.
Edge
Why consensus could be wrong
The market may be underestimating the potential for Indivior's new treatment options to drive higher-than-expected revenue growth.
Supporting Evidence
Indivior has consistently beaten EPS estimates, indicating stronger operational performance.
The options market is pricing in a significant move, suggesting that traders expect a positive surprise.
Recent trends in addiction treatment demand may not be fully reflected in current consensus estimates.
Key Risk
If the EPS comes in below $0.90, it would challenge the current bullish sentiment.
Edge
Pre-commit to what would confirm each case.
The upcoming earnings report is pivotal for assessing Indivior's growth trajectory and market confidence.
Bull Confirmed If
An EPS of $1.00 or higher would confirm strong operational performance and market demand.
Bear Confirmed If
An EPS below $0.90 could signal weakening demand and lead to a negative market reaction.
Pre-Earnings Positioning
Implied Move
±26.55%
Historical Avg
±9.9%
The options market is pricing in a substantial move, indicating that traders expect significant volatility around the earnings report.
Options are pricing ±26.6% while INDV has averaged ±9.9% over the last 4 prints — setup is pricing rich.
ATM IV
0.6%
30d HV
48.7%
Preparation
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Indivior beats expectations, history suggests a potential stock increase of around 9.86%, confirming strong demand.
In-Line / Cautious
If results are in line with expectations, the stock may experience a muted reaction, reflecting cautious investor sentiment.
Miss
A miss could lead to a decline, with historical patterns suggesting a drop of around 9.86% if expectations are not met.
Preparation
ONEOK, Inc.